Neurocrine Biosciences Reports 3rd Quarter 2026 Results - NEUROCRINE BIOSCIENCES INC

Explicit Guidance:

• Ingrezza (2026): Full-year sales guidance raised to $2.9–$2.925 billion (previously $2.7B); driven by underlying prescription growth in the high teens.
• Ingrezza (2027): Anticipated to deliver double-digit volume growth to offset anticipated mid-to-high single-digit net pricing headwinds; expects another year of revenue growth.
• Pricing Outlook: For 2027, expects mid-to-high single-digit net price concessions due to payer contracting, though full 2027 sales guidance will be formally provided in February 2027.
• Inreza Access: Approximately 70% of Medicare lives covered under 2025 contracting; expects coverage momentum to continue into Q4 2026 and 2027, with strong visibility for 2028 formulary status.

Business-Segment Outlook:

• Ingrezza: Nine years post-launch, still delivering double-digit prescription growth; ~50% of the Total Dystonia (TD) population diagnosed, with only ~10% of the prevalent population currently on VMAT2 inhibitors, leaving substantial headroom. Growth expected across psychiatry (advanced practice providers), neurology, and long-term care segments.
• Chronicity: Currently covers >15% of the estimated diagnosed classic Congenital Adrenal Hyperplasia (CAH) population; 7 quarters post-launch, still in early commercial ramp. Half of treated patients are now adults; strong persistency and favorable reimbursement expected to drive continued steady growth.
• Vicat XR: Q3 sales exceeded $100 million ($107M), driven by sequential growth in new patient demand. While growth trajectory may be slightly delayed due to external safety events, long-term potential remains strong. Average maintenance dose estimated at 250 mg (implying ~$550k WAC annually).
• Pipeline Inflection Points:
  • Phase III: Data readouts anticipated in 2027 for Osteo-Vampator (NBI-2118) and Major Depressive Disorder (NBI-567).
  • Phase III: Top-line data expected in 2027 for Ereclidine (Direct Leading) in Schizophrenia.
  • Phase I: NBI-223 (Friedreich's ataxia gene therapy) expected to enter Phase I in the coming months, with initial patient-level data in 2027.
  • Phase II: Study of NBI-567 (Alzheimer's) initiated; NBI-223 (FA) and NBI-1968 (Obesity) in Phase I.
  • Study Initiation: Phase II study for NBI-567 (Alzheimer's) ongoing; Phase I study for NBIP-1968 (Obesity) initiated; NBI-223 (FA) moving to Phase I.

Market and Competitive Outlook:

• Ingrezza: Differentiates from competitors via advanced practice provider focus and deep penetration in psychiatry; expects to maintain double-digit volume growth despite competitor activity.
• Ereclidine (Schizophrenia): Targets a market with limited new treatments for years; expects to win on safety and tolerability (once-daily, no titration, low discontinuation rate <3%) versus existing agents like Co-ben-vi (likely Co-Benve?).
• Vicat XR: First and only FDA-approved treatment for hyperphagia in PWS; estimated market of 10,000–12,000 patients in the US, with the majority having hyperphagia.
• Chronicity: Differentiates from Vertex's candidate via 5-year long-term data, physiological GC dosing in 70% of patients, normal androgen levels, and improved cardiometabolic outcomes.
• Obesity Franchise: Differentiating MBIP2118 (CRF2 agonist) aims for weight loss comparable to incretins but with muscle preservation and cardiac/renal benefits; NBIP-1968 (Triple G) developed as a standalone or combination partner.
• Alzheimer's: NBI-567 (M1 preferring agonist) positioned as adjunctive therapy to address cognitive decline in patients already on cholinesterase inhibitors.

Macro / Industry Outlook:

• Reimbursement: Chronicity and Vicat XR benefit from favorable reimbursement trends; Ingrezza maintains strong access with 2028 formulary status expected to match or exceed 2027 coverage.
• Regulatory: Active engagement with FDA regarding Vicat XR safety monitoring; collaboration planned for a study in PWS patients with complex comorbidities to expand knowledge of the disease and drug utility.
• Patents: Intellectual property runway for Vicat XR projected through the mid-2040s; confidence in exclusivity despite ongoing generic patent challenges.

Strategic Initiatives:

• R&D Day: Hosting 2026 R&D Day in NYC on December 15, 2026, featuring a panel with Dr. Jennifer Miller on PWS and pipeline updates.
• Pipeline Expansion: On track to deliver six Phase 1s and five new Phase 2 starts in 2026 (a company first); advancing a "deepest and most diversified pipeline" in history.
• Obesity Strategy: Exploring differentiated combinations (CRF2 agonist + Triple G agonist) and potential univalent molecules to leverage existing neuroendocrinology expertise.
• Business Development: Disciplined focus on opportunities in neurology, psychiatry, endocrinology, and emerging immunology; prioritizing differentiated science and strong IP; no immediate pressure to close a deal given financial flexibility.
• Sales Force: Expanded sales force deployment for Ingrezza is expected to yield full impact in Q4 2026 and 2027.
• Pipeline Pruning: Discontinued NBI-986 (M4 antagonist for movement disorders) following Phase 1 data review that did not meet go/no-go criteria (strategic decision, not safety-related).

Risks and Headwinds to Outlook:

• Vicat XR: Growth trajectory potentially delayed by recent external safety events; need for continued patient/physician education regarding dose titration and monitoring of adverse events (hyperglycemia, fluid retention).
• Ingrezza: Anticipated mid-to-high single-digit pricing headwinds in 2027, though expected to be offset by volume growth.
• Pipeline Execution: Reliance on successful Phase III readouts for Ereclidine (Schizophrenia) and Osteo-Vampator in 2027 to drive transformative growth.
• Competition: Future competition from Vertex (CAH) and other late-stage psychiatric assets; market dynamics for Ingrezza and Vicat XR remain subject to ongoing post-marketing safety surveillance.
• Clinical Outcomes: Uncertainty regarding dose-response for Ereclidine and potential efficacy/safety hurdles in early-stage obesity and Alzheimer's programs.

Management Tone on the Future:

• Confidence Level: Deeply confident and optimistic about driving sustained growth and creating long-term value; describes 2027 as a "potentially transformative period" and "data-rich."
• Momentum: Emphasizes record profitability, record sales, and strong operating leverage; views 2026 as the "strongest commercial year" in history.
• Caveats: Hedges Vicat XR growth expectations due to "external events" but maintains strong conviction in the benefit-risk profile; notes that orphan disease launches may not be linear.

Miscellaneous:

• Cash Position: Ended Q3 2026 with ~$800 million in cash and $400 million in operating cash flow; deployed $100 million for share repurchases.
• Capital Allocation: Priorities include driving commercial growth, advancing high-value pipeline programs, and disciplined business development.
• Share Count: Repurchases aimed at offsetting dilution from share-based compensation.